Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

by | Jul 19, 2024 | Press Releases

GAITHERSBURG, Md., July 19, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation...
Skip to content